This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
$1 buys you full access to ALL of TheStreet's Subscription Services! Learn More
EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stock Under $10 that he thinks could potentially double or triple in the next 6 to 12-months. See what he's trading today with a 14-day FREE pass.

Alnylam Pharmaceuticals Inc. (ALNY): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Alnylam Pharmaceuticals ( ALNY) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day up 1.8%. By the end of trading, Alnylam Pharmaceuticals fell $0.71 (-1.1%) to $65.73 on average volume. Throughout the day, 669,569 shares of Alnylam Pharmaceuticals exchanged hands as compared to its average daily volume of 779,400 shares. The stock ranged in price between $64.74-$67.97 after having opened the day at $67.15 as compared to the previous trading day's close of $66.44. Other companies within the Drugs industry that declined today were: Mast Therapeutics ( MSTX), down 41.3%, Tesaro ( TSRO), down 24.8%, Delcath Systems ( DCTH), down 6.5% and CytRx Corporation ( CYTR), down 6.2%.

Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, engages in discovering, developing, and commercializing novel therapeutics based on RNA interference (RNAi). Alnylam Pharmaceuticals has a market cap of $3.9 billion and is part of the health care sector. Shares are up 264.1% year to date as of the close of trading on Friday. Currently there are 5 analysts that rate Alnylam Pharmaceuticals a buy, no analysts rate it a sell, and 1 rates it a hold.

TheStreet Ratings rates Alnylam Pharmaceuticals as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity, weak operating cash flow and feeble growth in its earnings per share.

On the positive front, Cormedix ( CRMD), up 33.7%, United Therapeutics Corporation ( UTHR), up 30.4%, Can Fite Biofarma Ltd. ADR ( CANF), up 17.5% and Celator Pharmaceuticals ( CPXX), up 16.3% , were all gainers within the drugs industry with Endo Health Solutions ( ENDP) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
Submit an article to us!

Markets

DOW 17,827.75 +12.81 0.07%
S&P 500 2,072.83 +5.80 0.28%
NASDAQ 4,787.3170 +29.0650 0.61%

Brokerage Partners

Top Rated Stocks Top Rated Funds Top Rated ETFs